BioSpace News Archive

Drug Development

Oramed Announces Top-line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. announced top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes at 26 weeks.

January 11, 2023
·
4 min read
Biotech Bay

CareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium

CareDx Fosters Transplant Innovation as Distinguished Founder’s Circle Sponsor for the 23rd Annual American Society of Transplant Surgeons State of the Art Winter Symposium.

January 11, 2023
·
5 min read
Genetown

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

Intellia Therapeutics, Inc. today announced the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) has awarded the Innovation Passport for NTLA-2002, an in vivo genome editing candidate being developed for the treatment of hereditary angioedema (HAE).

January 11, 2023
·
7 min read
Business

KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

KemPharm, Inc. announced the promotions of Sven Guenther, Ph.D., to Chief Scientific Officer, and Christal M.M. Mickle, M.A., to Chief Product Development Officer.

January 11, 2023
·
6 min read
Business

Nephros Announces Preliminary Results for Fourth Quarter and Fiscal Year 2022

Nephros, Inc. today announced preliminary revenue results for the fourth quarter and fiscal year ended December 31, 2022.

January 11, 2023
·
2 min read
Drug Development

Aprea Therapeutics Announces Dosing of First Patient in Phase 1/2a Clinical Trial of Oral ATR Inhibitor ATRN-119 for the Treatment of Advanced Solid Tumors

Aprea Therapeutics, Inc. today announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company’s lead ATR inhibitor for the treatment of cancers with DDR mutations.

January 11, 2023
·
4 min read
Business

iCAD Announces Board of Directors Transition

iCAD, Inc. today announced the appointment of Dana Brown as Executive Chair of the Board of Directors.

January 11, 2023
·
4 min read
Drug Development

Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor

Fresh Tracks Therapeutics, Inc. today announced publication of data from preclinical studies of FRTX-02, a potential first-in-class, orally bioavailable DYRK1A inhibitor, in the Journal of Translational Autoimmunity.

January 11, 2023
·
9 min read
Business

ClearPoint Neuro Reports Fourth Quarter and Full Year 2022 Preliminary Revenue Results and Guidance for Full Year 2023 Revenue

ClearPoint Neuro, Inc. today announced preliminary, unaudited financial results for its fourth quarter and full year ended December 31, 2022.

January 11, 2023
·
5 min read
VERO Biotech Raises $30 Million to Accelerate Commercialization of Its Innovative Tankless Inhaled Nitric Oxide Delivery System

VERO Biotech Inc., a commercial-stage healthcare business dedicated to neonatal intensive care and the acute care hospital community, today announced the successful close of a $30 million financing with Petrichor, a leading healthcare-dedicated growth capital provider.

January 11, 2023
·
5 min read